CELLULAR BIOMEDICINE GROUP, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

Item 7.01 Regulation FD Disclosure.

Attached as Exhibit 99.1 to this Current Report is the form of presentation that Cellular Biomedicine Group, Inc. intends to use in connection with a virtual presentation to be held at 1:15PM Pacific Standard Time on Saturday, December 5, 2020 at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition. Attached as Exhibit 99.2 to this Current Report is the Press Release for the presentation.

The foregoing (including Exhibit 99.1 and Exhibit 99.2) is being furnished pursuant to Item 7.01 and will not be deemed to be filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise be subject to the liabilities of that section, nor will it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01. Financial Statements and Exhibits.

(d)      Exhibits

  99.1    Presentation, dated December 5, 2020

  99.2    Press Release, dated December 4, 2020

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

© Edgar Online, source Glimpses